To know whether mutations in this gene really contributed in the disease progression, the kinase domain region of BCR-ABL gene was PCR amplified and the PCR products were sequenced in all the 41 CML patients who were under imatinib treatment. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.